Literature DB >> 31136816

A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.

Joseph S Friedberg1, Melissa J Culligan2, Anne S Tsao3, Valerie Rusch4, Boris Sepesi5, Harvey I Pass6, Raphael Bueno7, Bryan Burt8, David J Sugarbaker8, Marc de Perrot9, Alex A Adjei10, Prasad S Adusumilli4, Fred R Hirsch11, Shakuntala M Malik12, David J Harpole13.   

Abstract

This article is a joint effort arising from a task force formed at a National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting, held at the NIH in March 2017. Malignant pleural mesothelioma remains one of the most virulent and recalcitrant malignancies, still considered incurable, and in desperate need of clinical trials in order to make progress for our patients. Although not standard of care, there is compelling evidence that a select subgroup of mesothelioma patients benefit from a surgery-based multimodal approach. As it is not possible to achieve a microscopically complete resection with mesothelioma, there appears to be no role for surgery alone. Thus, it is anticipated that significant strides in the surgery-based treatment of this cancer will require trials that determine which complementary treatments best augment the cytoreductive efficacy of surgery. Although lung-sacrificing surgery for mesothelioma is fairly standardized, approaches to lung-sparing surgery are highly variable and lung sparing surgery is emerging internationally as the dominant extirpative procedure for this cancer. It is not currently possible to rigorously assess the contribution of the adjuvant treatments combined with surgery because of the variability in procedures used to debulk this cancer, the extreme variability of the cancer itself, the variability in patient selection, the variability in treatment of the inevitable recurrence, and even the variability in follow up schedules. This article is an effort to address these problems by suggesting a more uniform approach to the surgical procedure and also proposing a series of data collection forms that could be adopted immediately, with any eye toward collecting the information that will be necessary to facilitate patient selection and determine which aspects of mesothelioma surgery can and should be standardized - with the goal being extension of life while maintaining quality of life as an equal priority. Furthermore, a completely original contribution in this manuscript is the proposal of a grading system that takes the information from the surgical procedure data forms and generates a completeness of resection score. This is the initial effort to establish a common denominator for mesothelioma surgery that will allow for more accurate comparison between surgical series and better assessment of the impact of the treatments combined with surgery. Crown
Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lung-sparing surgery; Malignant pleural mesothelioma

Mesh:

Year:  2019        PMID: 31136816     DOI: 10.1016/j.jtho.2019.04.029

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  8 in total

1.  What has changed in malignant mesothelioma between 1990 and 2019? A time- series analyses in Turkey.

Authors:  Selma Metintas; Guntulu Ak; Emine Dundar; Muzaffer Metintas
Journal:  Int J Clin Oncol       Date:  2022-04-21       Impact factor: 3.402

Review 2.  New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.

Authors:  Anne S Tsao; Harvey I Pass; Andreas Rimner; Aaron S Mansfield
Journal:  J Clin Oncol       Date:  2022-01-05       Impact factor: 44.544

3.  Rethought histologic classification of pleural mesothelioma to better treat: go forward from looking back.

Authors:  Philippe Astoul
Journal:  Transl Lung Cancer Res       Date:  2020-08

Review 4.  Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.

Authors:  Steven G Gray
Journal:  BMC Pulm Med       Date:  2021-05-05       Impact factor: 3.317

5.  Long-term outcomes after lung-sparing surgery for epithelial mesothelioma.

Authors:  Cristiano Breda; Simone Furia; Giuseppe Lucchini; Antonio Zaccaria; Enrico Verderi; Giuseppe Natale; Fabio Lo Giudice; Roberta Cavallin; Andrea Ferronato; Paolo Fontana
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

Review 6.  Molecular Mechanisms of Autophagy in Cancer Development, Progression, and Therapy.

Authors:  Veronica Angela Maria Vitto; Silvia Bianchin; Alicia Ann Zolondick; Giulia Pellielo; Alessandro Rimessi; Diego Chianese; Haining Yang; Michele Carbone; Paolo Pinton; Carlotta Giorgi; Simone Patergnani
Journal:  Biomedicines       Date:  2022-07-05

7.  Extended pleurectomy and decortication: Video atlas of operative steps.

Authors:  R Taylor Ripley; Nihanth Palivela
Journal:  JTCVS Tech       Date:  2021-03-24

Review 8.  Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.

Authors:  Steven G Gray; Luciano Mutti
Journal:  Transl Lung Cancer Res       Date:  2020-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.